Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an anthracycline, a taxane, and capecitabine.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb; R-Pharm
• Treatments: Epothilones

Criteria

Inclusion Criteria:

• Patients must have received all 3 drugs- an anthracycline, taxane, and capecitabine (alone or in combination) and be resistant

• No more than 3 prior chemotherapy regimens in the metastatic setting

• Must have at least one target lesion that is radiographically measurable

• Good performance status

• No history of or current brain or leptomeningeal disease